Marshall Wace LLP Purchases 315,182 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Marshall Wace LLP boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 496.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 378,649 shares of the biopharmaceutical company's stock after purchasing an additional 315,182 shares during the period. Marshall Wace LLP owned about 0.29% of Alnylam Pharmaceuticals worth $89,100,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares in the last quarter. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $33,000. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. Versant Capital Management Inc boosted its position in Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 83 shares during the period. Finally, IFP Advisors Inc grew its holdings in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ALNY shares. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Royal Bank of Canada upped their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $315.58.

Alnylam Pharmaceuticals Stock Up 0.4 %

NASDAQ ALNY traded up $0.91 during trading hours on Tuesday, hitting $233.66. The company's stock had a trading volume of 114,229 shares, compared to its average volume of 869,398. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company's 50-day simple moving average is $248.47 and its two-hundred day simple moving average is $256.64. The company has a market capitalization of $30.40 billion, a PE ratio of -107.82 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Pushkal Garg sold 1,548 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.